T cell receptor engineering

Jennifer D. Stone, Adam S. Chervin, David H. Aggen, David M Kranz

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

T lymphocytes express on their surface a heterodimeric αβ receptor, called the T cell receptor (TCR), which recognizes foreign antigens. Unlike antibodies, the recognition requires both an antigenic peptide epitope and a protein encoded by the major histocompatibility complex (MHC). In contrast to conventional antibody-directed target antigens, antigens recognized by the TCR can include the entire array of potential intracellular proteins, which are processed and delivered to the cell surface as a peptide/MHC complex. In the past 10 years, there have been significant efforts to engineer TCRs in various formats, which would allow improved recognition and destruction of virus-infected cells or cancer. The proposed therapeutic approaches involve either the use of engineered, high-affinity TCRs in soluble forms, analogous to antibody-directed therapies, or the use of engineered TCRs whose genes are reintroduced into autologous T cells and transferred back into patients (T cell adoptive therapies). This chapter describes three methods associated with the engineering of TCRs for these therapeutic purposes: (1) use of a yeast display system to engineer higher affinity single-chain VαVβ TCRs, called scTv; (2) use of a T cell display system to engineer higher affinity full-length TCRs; and (3) expression, purification, and characterization of soluble TCRs in an Escherichia coli system.

Original languageEnglish (US)
Title of host publicationMethods in Enzymology
PublisherAcademic Press Inc.
Pages189-222
Number of pages34
DOIs
StatePublished - 2012

Publication series

NameMethods in Enzymology
Volume503
ISSN (Print)0076-6879
ISSN (Electronic)1557-7988

Fingerprint

Cell Engineering
T-cells
T-Cell Antigen Receptor
T-Lymphocytes
Major Histocompatibility Complex
Antigens
Engineers
Antibodies
Display devices
Peptides
Cell- and Tissue-Based Therapy
Viruses
Yeast
Escherichia coli
Purification
Epitopes
Proteins
Therapeutics
Genes
Yeasts

Keywords

  • Complementarity-determining regions
  • Fluorescence-activated cell sorting
  • Keywords
  • Major histocompatibility complex
  • Protein engineering
  • Splicing by overlap extension
  • T cell display
  • T cell receptor
  • Yeast display

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Stone, J. D., Chervin, A. S., Aggen, D. H., & Kranz, D. M. (2012). T cell receptor engineering. In Methods in Enzymology (pp. 189-222). (Methods in Enzymology; Vol. 503). Academic Press Inc.. https://doi.org/10.1016/B978-0-12-396962-0.00008-2

T cell receptor engineering. / Stone, Jennifer D.; Chervin, Adam S.; Aggen, David H.; Kranz, David M.

Methods in Enzymology. Academic Press Inc., 2012. p. 189-222 (Methods in Enzymology; Vol. 503).

Research output: Chapter in Book/Report/Conference proceedingChapter

Stone, JD, Chervin, AS, Aggen, DH & Kranz, DM 2012, T cell receptor engineering. in Methods in Enzymology. Methods in Enzymology, vol. 503, Academic Press Inc., pp. 189-222. https://doi.org/10.1016/B978-0-12-396962-0.00008-2
Stone JD, Chervin AS, Aggen DH, Kranz DM. T cell receptor engineering. In Methods in Enzymology. Academic Press Inc. 2012. p. 189-222. (Methods in Enzymology). https://doi.org/10.1016/B978-0-12-396962-0.00008-2
Stone, Jennifer D. ; Chervin, Adam S. ; Aggen, David H. ; Kranz, David M. / T cell receptor engineering. Methods in Enzymology. Academic Press Inc., 2012. pp. 189-222 (Methods in Enzymology).
@inbook{fae304e82d06450a8c44c7422760b653,
title = "T cell receptor engineering",
abstract = "T lymphocytes express on their surface a heterodimeric αβ receptor, called the T cell receptor (TCR), which recognizes foreign antigens. Unlike antibodies, the recognition requires both an antigenic peptide epitope and a protein encoded by the major histocompatibility complex (MHC). In contrast to conventional antibody-directed target antigens, antigens recognized by the TCR can include the entire array of potential intracellular proteins, which are processed and delivered to the cell surface as a peptide/MHC complex. In the past 10 years, there have been significant efforts to engineer TCRs in various formats, which would allow improved recognition and destruction of virus-infected cells or cancer. The proposed therapeutic approaches involve either the use of engineered, high-affinity TCRs in soluble forms, analogous to antibody-directed therapies, or the use of engineered TCRs whose genes are reintroduced into autologous T cells and transferred back into patients (T cell adoptive therapies). This chapter describes three methods associated with the engineering of TCRs for these therapeutic purposes: (1) use of a yeast display system to engineer higher affinity single-chain VαVβ TCRs, called scTv; (2) use of a T cell display system to engineer higher affinity full-length TCRs; and (3) expression, purification, and characterization of soluble TCRs in an Escherichia coli system.",
keywords = "Complementarity-determining regions, Fluorescence-activated cell sorting, Keywords, Major histocompatibility complex, Protein engineering, Splicing by overlap extension, T cell display, T cell receptor, Yeast display",
author = "Stone, {Jennifer D.} and Chervin, {Adam S.} and Aggen, {David H.} and Kranz, {David M}",
year = "2012",
doi = "10.1016/B978-0-12-396962-0.00008-2",
language = "English (US)",
series = "Methods in Enzymology",
publisher = "Academic Press Inc.",
pages = "189--222",
booktitle = "Methods in Enzymology",
address = "United States",

}

TY - CHAP

T1 - T cell receptor engineering

AU - Stone, Jennifer D.

AU - Chervin, Adam S.

AU - Aggen, David H.

AU - Kranz, David M

PY - 2012

Y1 - 2012

N2 - T lymphocytes express on their surface a heterodimeric αβ receptor, called the T cell receptor (TCR), which recognizes foreign antigens. Unlike antibodies, the recognition requires both an antigenic peptide epitope and a protein encoded by the major histocompatibility complex (MHC). In contrast to conventional antibody-directed target antigens, antigens recognized by the TCR can include the entire array of potential intracellular proteins, which are processed and delivered to the cell surface as a peptide/MHC complex. In the past 10 years, there have been significant efforts to engineer TCRs in various formats, which would allow improved recognition and destruction of virus-infected cells or cancer. The proposed therapeutic approaches involve either the use of engineered, high-affinity TCRs in soluble forms, analogous to antibody-directed therapies, or the use of engineered TCRs whose genes are reintroduced into autologous T cells and transferred back into patients (T cell adoptive therapies). This chapter describes three methods associated with the engineering of TCRs for these therapeutic purposes: (1) use of a yeast display system to engineer higher affinity single-chain VαVβ TCRs, called scTv; (2) use of a T cell display system to engineer higher affinity full-length TCRs; and (3) expression, purification, and characterization of soluble TCRs in an Escherichia coli system.

AB - T lymphocytes express on their surface a heterodimeric αβ receptor, called the T cell receptor (TCR), which recognizes foreign antigens. Unlike antibodies, the recognition requires both an antigenic peptide epitope and a protein encoded by the major histocompatibility complex (MHC). In contrast to conventional antibody-directed target antigens, antigens recognized by the TCR can include the entire array of potential intracellular proteins, which are processed and delivered to the cell surface as a peptide/MHC complex. In the past 10 years, there have been significant efforts to engineer TCRs in various formats, which would allow improved recognition and destruction of virus-infected cells or cancer. The proposed therapeutic approaches involve either the use of engineered, high-affinity TCRs in soluble forms, analogous to antibody-directed therapies, or the use of engineered TCRs whose genes are reintroduced into autologous T cells and transferred back into patients (T cell adoptive therapies). This chapter describes three methods associated with the engineering of TCRs for these therapeutic purposes: (1) use of a yeast display system to engineer higher affinity single-chain VαVβ TCRs, called scTv; (2) use of a T cell display system to engineer higher affinity full-length TCRs; and (3) expression, purification, and characterization of soluble TCRs in an Escherichia coli system.

KW - Complementarity-determining regions

KW - Fluorescence-activated cell sorting

KW - Keywords

KW - Major histocompatibility complex

KW - Protein engineering

KW - Splicing by overlap extension

KW - T cell display

KW - T cell receptor

KW - Yeast display

UR - http://www.scopus.com/inward/record.url?scp=84855584055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855584055&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-396962-0.00008-2

DO - 10.1016/B978-0-12-396962-0.00008-2

M3 - Chapter

C2 - 22230570

AN - SCOPUS:84855584055

T3 - Methods in Enzymology

SP - 189

EP - 222

BT - Methods in Enzymology

PB - Academic Press Inc.

ER -